Therapeutics for Immune System Disorders

This study surveys the market for small–molecules and biologic therapies for diseases caused by disorders of the immune system: therapies covered are either already used or will be used as medicine within the next 5 years. Promising drugs in the early stages of development are analyzed, but the emphasis is strongly upon drugs that are either on the market, or will be on the market within the time frame of this study.

 

In addition to profiling drugs and explaining the mechanism by which these drugs achieve their efficacy, the report breaks out the major medical markets for immune disease. This report does not cover drugs in pre–clinical testing in detail – even though some of the drugs with novel approaches are mentioned in the appropriate sections of the report. The report does not cover drugs that act to enhance the activity of the immune system against diseases such as cancer or opportunistic infections. Even though mechanisms of certain drugs help in the treatment of various cancer indications as well as immune diseases and are indicated for both, sales to those cancer–related indications are excluded as much as possible. Another therapeutic area that is excluded is Type–1 diabetes, though it is indeed an immune disease. This is excluded because most of the drugs are commonly used for both types of diabetes, and it is difficult to get an accurate idea about the sales exclusively for managing Type–1. Additionally, medical devices, or the direct costs of surgery to treat immune diseases, etc., are not covered. We believe that the market dynamics of these products and services are dramatically different than the pharmaceutical market and need to be dealt with as a separate report. 

 

In general, this report contains:

Syamala Ariyanchira is actively involved in technology assessment, strategic planning, competitor analysis, due diligence, and market analysis. She easily combines her technical background with business sector issues. Her clients include investment firms, government agencies, and chemical and pharmaceutical companies. She holds a Ph.D. from Indian Institute of Science, Bangalore, India, and has more than 15 years of experience in the industry. She is currently an associate with Singapore–based consultancy firm Polybus Consulting Pte Ltd. (www.polybus–consulting.com).